nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Abstracts 209-273
|
|
|
2001 |
|
1_suppl |
p. 73-89 |
artikel |
2 |
Abstracts 98
|
|
|
2001 |
|
1_suppl |
p. 98 |
artikel |
3 |
Abstracts 69-136
|
|
|
2001 |
|
1_suppl |
p. 30-46 |
artikel |
4 |
Abstracts 1-6
|
|
|
2001 |
|
1_suppl |
p. 8-9 |
artikel |
5 |
Abstracts 44-51
|
|
|
2001 |
|
1_suppl |
p. 96-97 |
artikel |
6 |
Abstracts 94-95
|
|
|
2001 |
|
1_suppl |
p. 94-95 |
artikel |
7 |
Abstracts 17-18
|
|
|
2001 |
|
1_suppl |
p. 12 |
artikel |
8 |
Abstracts 19-26
|
|
|
2001 |
|
1_suppl |
p. 50-51 |
artikel |
9 |
Abstracts 9-16
|
|
|
2001 |
|
1_suppl |
p. 10-11 |
artikel |
10 |
Abstracts 27-34
|
|
|
2001 |
|
1_suppl |
p. 52-53 |
artikel |
11 |
Abstracts 274-329
|
|
|
2001 |
|
1_suppl |
p. 99-112 |
artikel |
12 |
Abstracts 35
|
|
|
2001 |
|
1_suppl |
p. 54 |
artikel |
13 |
Abstracts 137-208
|
|
|
2001 |
|
1_suppl |
p. 55-72 |
artikel |
14 |
Abstracts 330-385
|
|
|
2001 |
|
1_suppl |
p. 113-126 |
artikel |
15 |
Abstracts 1-68
|
|
|
2001 |
|
1_suppl |
p. 13-29 |
artikel |
16 |
Abstracts for the 16th International Congress on Antiphospholipid Antibodies (ICAPA)
|
|
|
2019 |
|
1_suppl |
p. 3-63 |
artikel |
17 |
Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus
|
Lewis, MJ |
|
2005 |
|
1_suppl |
p. 17-26 |
artikel |
18 |
Amaurosis fugax, Crohn's Disease and the Anticardiolipin Antibody
|
Greenfield, S.M. |
|
1993 |
|
1_suppl |
p. 271-273 |
artikel |
19 |
Antimalarial drugs in pregnancy – the North American experience
|
Parke, AL |
|
1996 |
|
1_suppl |
p. 67-69 |
artikel |
20 |
Antimalarial drugs in pregnancy – the North American experience
|
Parke, AL |
|
1996 |
|
1_suppl |
p. 67-69 |
artikel |
21 |
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development
|
Fox, R |
|
1996 |
|
1_suppl |
p. 4-10 |
artikel |
22 |
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development
|
Fox, R |
|
1996 |
|
1_suppl |
p. 4-10 |
artikel |
23 |
Antimalarial Drugs, Pregnancy and Lactation
|
Parke, Ann L. |
|
1993 |
|
1_suppl |
p. 21-23 |
artikel |
24 |
Antimalarial Drugs, Pregnancy and Lactation
|
Parke, Ann L. |
|
1993 |
|
1_suppl |
p. 21-23 |
artikel |
25 |
Antimalarials in Sjogren's syndrome-the Greek experience
|
Manoussakis, MN |
|
1996 |
|
1_suppl |
p. 28-30 |
artikel |
26 |
Antimalarials in Sjogren's syndrome-the Greek experience
|
Manoussakis, MN |
|
1996 |
|
1_suppl |
p. 28-30 |
artikel |
27 |
Antiphospholipid syndrome in obstetrics
|
Kemp, M |
|
2018 |
|
1_suppl |
p. 28-31 |
artikel |
28 |
Author Index
|
|
|
2001 |
|
1_suppl |
p. 127-136 |
artikel |
29 |
Case Report Hepatic Infarction in a Pregnant Patient with the ‘Primary’ Antiphospholipid Syndrome
|
Millán-Mon, A. |
|
1993 |
|
1_suppl |
p. 275-279 |
artikel |
30 |
Case Report Pericardial Complication of Neuropsychiatric Systemic Lupus Erythematosus
|
Sarkar, David |
|
1993 |
|
1_suppl |
p. 269-270 |
artikel |
31 |
Commonly used medication for Lupus
|
Yates, M |
|
2018 |
|
1_suppl |
p. 8-10 |
artikel |
32 |
Detection of Anti-Phospholipid and Anti-DNA Antibodies and their Idiotypes in Newborns of Mothers with Anti-Phospholipid Syndrome and Sle
|
Zurgil, N. |
|
1993 |
|
1_suppl |
p. 233-237 |
artikel |
33 |
Detection of Anti-Phospholipid and Anti-DNA Antibodies and their Idiotypes in Newborns of Mothers with Anti-Phospholipid Syndrome and Sle
|
Zurgil, N. |
|
1993 |
|
1_suppl |
p. 233-237 |
artikel |
34 |
Effect of Sex on the Induction of Anti-DNA Antibodies in Normal Mice Immunized with Bacterial DNA
|
Palmer, Scott M. |
|
1993 |
|
1_suppl |
p. 251-255 |
artikel |
35 |
Effect of Sex on the Induction of Anti-DNA Antibodies in Normal Mice Immunized with Bacterial DNA
|
Palmer, Scott M. |
|
1993 |
|
1_suppl |
p. 251-255 |
artikel |
36 |
Foreword: Antimalarials in rheumatology
|
Hughes, G |
|
1996 |
|
1_suppl |
p. 1 |
artikel |
37 |
Foreword: Antimalarials in rheumatology
|
Hughes, G |
|
1996 |
|
1_suppl |
p. 1 |
artikel |
38 |
Hughes syndrome (antiphospholipid syndrome) and the nervous system
|
Hughes, G |
|
2018 |
|
1_suppl |
p. 15-17 |
artikel |
39 |
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis
|
Petri, M |
|
1996 |
|
1_suppl |
p. 16-22 |
artikel |
40 |
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis
|
Petri, M |
|
1996 |
|
1_suppl |
p. 16-22 |
artikel |
41 |
ICAPA Abstracts Index
|
|
|
2019 |
|
1_suppl |
p. 64-67 |
artikel |
42 |
Instructions for Contributors
|
|
|
1993 |
|
1_suppl |
p. 224-225 |
artikel |
43 |
Instructions for Contributors
|
|
|
1993 |
|
1_suppl |
p. 224-225 |
artikel |
44 |
Interstitial Inflammatory and Chronic Tubulointerstitial Lesions in Lupus Nephritis: Comparison with those in IgA Nephropathy
|
Yamamoto, Tatsuo |
|
1993 |
|
1_suppl |
p. 261-268 |
artikel |
45 |
Introduction
|
Hughes, Graham Rv |
|
2005 |
|
1_suppl |
p. 1 |
artikel |
46 |
Introduction
|
Rynes, Richard I. |
|
1993 |
|
1_suppl |
p. 1 |
artikel |
47 |
Introduction
|
Hughes, Graham |
|
2018 |
|
1_suppl |
p. 3 |
artikel |
48 |
Introduction
|
Rynes, Richard I. |
|
1993 |
|
1_suppl |
p. 1 |
artikel |
49 |
Lupus Nephritis: Induction Therapy
|
Chan, TM |
|
2005 |
|
1_suppl |
p. 27-32 |
artikel |
50 |
Lymphocyte Subsets in a Large Cohort of Patients with Systemic Lupus Erythematosus
|
Erkeller-Yüksel, Feza |
|
1993 |
|
1_suppl |
p. 227-231 |
artikel |
51 |
Lymphocyte Subsets in a Large Cohort of Patients with Systemic Lupus Erythematosus
|
Erkeller-Yüksel, Feza |
|
1993 |
|
1_suppl |
p. 227-231 |
artikel |
52 |
Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide
|
Contreras, G |
|
2005 |
|
1_suppl |
p. 33-38 |
artikel |
53 |
Management of pregnancy in systemic lupus erythematosus: What a GP should know
|
Jordan, N |
|
2018 |
|
1_suppl |
p. 40-43 |
artikel |
54 |
Maternal Autoantibodies and Congenital Heart Block: No Evidence for the Existence of a Unique Heart Block-associated Anti-Ro/SS-A Autoantibody Profile
|
Meilof, J.F. |
|
1993 |
|
1_suppl |
p. 239-246 |
artikel |
55 |
Maternal Autoantibodies and Congenital Heart Block: No Evidence for the Existence of a Unique Heart Block-associated Anti-Ro/SS-A Autoantibody Profile
|
Meilof, J.F. |
|
1993 |
|
1_suppl |
p. 239-246 |
artikel |
56 |
Mechanism of Action of Antimalarial Drugs: Inhibition of Antigen Processing and Presentation
|
Fox, Robert I. |
|
1993 |
|
1_suppl |
p. 9-12 |
artikel |
57 |
Mechanism of Action of Antimalarial Drugs: Inhibition of Antigen Processing and Presentation
|
Fox, Robert I. |
|
1993 |
|
1_suppl |
p. 9-12 |
artikel |
58 |
Mechanisms of action of mycophenolate mofetil
|
Allison, AC |
|
2005 |
|
1_suppl |
p. 2-8 |
artikel |
59 |
MMF and Eye Disease
|
Zierhut, M |
|
2005 |
|
1_suppl |
p. 50-54 |
artikel |
60 |
Mycophenolate mofetil and myasthenia gravis
|
Ciafaloni, E |
|
2005 |
|
1_suppl |
p. 46-49 |
artikel |
61 |
Mycophenolate mofetil and neurological diseases
|
Vermersch, P |
|
2005 |
|
1_suppl |
p. 42-45 |
artikel |
62 |
Mycophenolate mofetil and skin diseases
|
Hartmann, M |
|
2005 |
|
1_suppl |
p. 58-63 |
artikel |
63 |
Mycophenolate mofetil and systemic lupus erythematosus: an overview
|
Pisoni, CN |
|
2005 |
|
1_suppl |
p. 9-11 |
artikel |
64 |
Mycophenolate mofetil in animal models of autoimmune disease
|
Zandman-Goddard, G |
|
2005 |
|
1_suppl |
p. 12-16 |
artikel |
65 |
Mycophenolate mofetil in nonlupus glomerulonephropathy
|
Karim, MY |
|
2005 |
|
1_suppl |
p. 39-41 |
artikel |
66 |
Mycophenolate mofetil in patients with hepatitis C virus infection
|
Ramos-Casals, M |
|
2005 |
|
1_suppl |
p. 64-72 |
artikel |
67 |
Mycophenolate mofetil in systemic vasculitis
|
D'cruz, DP |
|
2005 |
|
1_suppl |
p. 55-57 |
artikel |
68 |
Neuropsychiatric symptoms in lupus
|
Lynall, M |
|
2018 |
|
1_suppl |
p. 18-20 |
artikel |
69 |
Ophthalmologic considerations in using antimalarials in the United States
|
Rynes, Richard I |
|
1996 |
|
1_suppl |
p. 73-74 |
artikel |
70 |
Ophthalmologic considerations in using antimalarials in the United States
|
Rynes, Richard I |
|
1996 |
|
1_suppl |
p. 73-74 |
artikel |
71 |
Ophthalmologic Safety Profile of Antimalarial Drugs
|
Rynes, Richard I. |
|
1993 |
|
1_suppl |
p. 17-19 |
artikel |
72 |
Ophthalmologic Safety Profile of Antimalarial Drugs
|
Rynes, Richard I. |
|
1993 |
|
1_suppl |
p. 17-19 |
artikel |
73 |
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases
|
Furst, Daniel E |
|
1996 |
|
1_suppl |
p. 11-15 |
artikel |
74 |
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases
|
Furst, Daniel E |
|
1996 |
|
1_suppl |
p. 11-15 |
artikel |
75 |
Primary Sjögren's syndrome
|
Bowman, SJ |
|
2018 |
|
1_suppl |
p. 32-35 |
artikel |
76 |
Reflex Seizures as Initial Manifestations of Systemic Lupus Erythematosus in Childhood
|
Brinciotti, Mario |
|
1993 |
|
1_suppl |
p. 281-283 |
artikel |
77 |
Relationship of IL-2, IL-2R (CD25+), Soluble IL-2R and IL-4 with Disease Activity in SLE Patients
|
Cuadrado, Maria J. |
|
1993 |
|
1_suppl |
p. 257-260 |
artikel |
78 |
Retinopathy and antimalarial drugs – the British experience
|
Spalton, DJ |
|
1996 |
|
1_suppl |
p. 70-72 |
artikel |
79 |
Retinopathy and antimalarial drugs – the British experience
|
Spalton, DJ |
|
1996 |
|
1_suppl |
p. 70-72 |
artikel |
80 |
Role of antimalarials in rheumatoid arthritis – the British experience
|
Davis, MJ |
|
1996 |
|
1_suppl |
p. 37-40 |
artikel |
81 |
Role of antimalarials in rheumatoid arthritis – the British experience
|
Davis, MJ |
|
1996 |
|
1_suppl |
p. 37-40 |
artikel |
82 |
Standardized Ultraviolet-A Exposure Provokes Skin Reaction in Systemic Lupus Erythematosus
|
Nived, Ola |
|
1993 |
|
1_suppl |
p. 247-250 |
artikel |
83 |
Standardized Ultraviolet-A Exposure Provokes Skin Reaction in Systemic Lupus Erythematosus
|
Nived, Ola |
|
1993 |
|
1_suppl |
p. 247-250 |
artikel |
84 |
The Big 3
|
Hughes, G |
|
2018 |
|
1_suppl |
p. 4-7 |
artikel |
85 |
The efficacy of antimalarials in systemic lupus erythematosus
|
Nayak, V |
|
1996 |
|
1_suppl |
p. 23-27 |
artikel |
86 |
The Efficacy of Antimalarials in Systemic Lupus Erythematosus
|
Esdaile, John M. |
|
1993 |
|
1_suppl |
p. 3-8 |
artikel |
87 |
The efficacy of antimalarials in systemic lupus erythematosus
|
Nayak, V |
|
1996 |
|
1_suppl |
p. 23-27 |
artikel |
88 |
The Efficacy of Antimalarials in Systemic Lupus Erythematosus
|
Esdaile, John M. |
|
1993 |
|
1_suppl |
p. 3-8 |
artikel |
89 |
The history of antimalarials
|
Wallace, DJ |
|
1996 |
|
1_suppl |
p. 2-3 |
artikel |
90 |
The history of antimalarials
|
Wallace, DJ |
|
1996 |
|
1_suppl |
p. 2-3 |
artikel |
91 |
The Relevance of Antimalarial Therapy with Regard to Thrombosis, Hypercholesterolemia and Cytokines in SLE
|
Wallace, Daniel J. |
|
1993 |
|
1_suppl |
p. 13-15 |
artikel |
92 |
The Relevance of Antimalarial Therapy with Regard to Thrombosis, Hypercholesterolemia and Cytokines in SLE
|
Wallace, Daniel J. |
|
1993 |
|
1_suppl |
p. 13-15 |
artikel |
93 |
The role of anti-malarials in rheumatoid arthritis – the American experience
|
Khraishi, Mm |
|
1996 |
|
1_suppl |
p. 41-44 |
artikel |
94 |
The role of anti-malarials in rheumatoid arthritis – the American experience
|
Khraishi, Mm |
|
1996 |
|
1_suppl |
p. 41-44 |
artikel |
95 |
The 9th International Congress on SLE June 24 – 27 2010, Vancouver, Canada
|
|
|
2010 |
|
1_suppl |
p. 1-185 |
artikel |
96 |
The use of antimalarials in combination with other disease modifying agents in RA – the British experience
|
Duncan, MR |
|
1996 |
|
1_suppl |
p. 50-58 |
artikel |
97 |
The use of antimalarials in combination with other disease modifying agents in RA – the British experience
|
Duncan, MR |
|
1996 |
|
1_suppl |
p. 50-58 |
artikel |
98 |
The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis–the French Experience
|
Kahan, A |
|
1996 |
|
1_suppl |
p. 45-49 |
artikel |
99 |
The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis–the French Experience
|
Kahan, A |
|
1996 |
|
1_suppl |
p. 45-49 |
artikel |
100 |
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review
|
Wallace, DJ |
|
1996 |
|
1_suppl |
p. 59-64 |
artikel |
101 |
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review
|
Wallace, DJ |
|
1996 |
|
1_suppl |
p. 59-64 |
artikel |
102 |
The use of hydroxychloroquine in lupus pregnancy: the British experience
|
Khamashta, MA |
|
1996 |
|
1_suppl |
p. 65-66 |
artikel |
103 |
The use of hydroxychloroquine in lupus pregnancy: the British experience
|
Khamashta, MA |
|
1996 |
|
1_suppl |
p. 65-66 |
artikel |
104 |
15th International Congress on Antiphospholipid Antibodies
|
|
|
2016 |
|
1_suppl |
p. 1-3 |
artikel |
105 |
15th International Congress on Antiphospholipid Antibodies – Abstract Index
|
|
|
2016 |
|
1_suppl |
p. 101-104 |
artikel |
106 |
15th International Congress on Antiphospholipid Antibodies Abstract Presentations
|
|
|
2016 |
|
1_suppl |
p. 4-100 |
artikel |
107 |
Thrombotic antiphospholipid syndrome
|
Sciascia, S |
|
2018 |
|
1_suppl |
p. 21-27 |
artikel |
108 |
Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study
|
Fox, Ri |
|
1996 |
|
1_suppl |
p. 31-36 |
artikel |
109 |
Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study
|
Fox, Ri |
|
1996 |
|
1_suppl |
p. 31-36 |
artikel |
110 |
Update on Lupus Nephritis for GPs
|
McClure, M |
|
2018 |
|
1_suppl |
p. 11-14 |
artikel |
111 |
Vaccination in SLE patients
|
Htut, EEP |
|
2018 |
|
1_suppl |
p. 36-39 |
artikel |